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Current practice guidelines recommend coronary artery bypass grafting (CABG)
as the standard procedure for patients with unprotected LMCA disease.
1,2
However, percutaneous coronary intervention (PCI) for LMCA disease was
attractive to the interventional cardiologist, and data from several registries
showed its feasibility and short- and mid-term-effectiveness. Nevertheless, PCI
for LMCA disease has been confined to surgically high-risk patients and those
with protected LMCA disease, or has been used as bailout procedures in patients
with angioplasty complications. 
The introduction of coronary stenting has led to a reevaluation of the role of
PCI as a viable treatment option for LMCA disease, and the widespread availa-
bility of drug-eluting stents (DES), together with improved stenting techniques,
has lowered the threshold for the use of PCI, instead of CABG, in patients with
LMCA disease. There has been little evaluation, however, of the long-term safety
and efficacy of PCI with stenting for unprotected LMCA disease, and no rando-
mized trial has compared the two primary interventions (PCI vs. CABG) in a large
population. We have therefore reviewed recent advances and the current status of
percutaneous vs. surgical treatment for LMCA disease, focusing on whether PCI
is an alternative to or a possible replacement for CABG in these patients. 
Bare-metal stents and drug-eluting stents 
Clinical results of stenting in patients chosen for PCI, either because of prohibitive
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INTRODUCTION
PERCUTANEOUS CORONARY INTERVENTION 
WITH STENTINGsurgical risk or as a bailout for angioplasty complications,
depend mainly upon baseline clinical characteristics, such
as left ventricular function and coexisting conditions. The
ULTIMA registry enrolled 279 patients with unprotected
LMCA stenosis who were treated with bare-metal stents
(BMS); of these, 46% were inoperable or at high surgical
risk. Among these high-risk patients, the in-hospital
mortality was 13.7%, and the 1-year incidence of all-cause
mortality was 24.2%; whereas among the 32% patients at
low risk (age < 65 years, ejection fraction > 30%), there
were no periproce-dural deaths and the 1-year mortality
rate was only 3.4%.
3 In a series of elective, low-risk
patients, who were also not at increased risk for CABG,
PCI with BMS for unprotected LMCA disease showed
favorable short- or mid-term outcomes (in-hospital
mortality, 0-4.3%; mortality at 6-12 months, 2.5-10.8%).
4-8
However, considerable risks of restenosis (18-31%) and
repeat revascularization (7.3-33.6%) have limited the
durability of LMCA stenting with BMS, because the
development of restenosis in such patients may lead to
worst-case outcomes, such as sudden death or acute MI. 
With advances in stenting techniques, the availability of
DES, and adjuvant pharmacotherapy such as clopidogrel,
statins and antiplatelet therapy, many experienced inter-
ventional cardiologists now perform PCI with stenting for
patients with unprotected LMCA disease. Several observa-
tional studies, although limited by its non-randomized
nature, small number of patients, and short follow-up
periods, have shown promising PCI outcomes using DES
compared with BMS.
9-11 Most initial reports documented
that DES afforded higher procedural success rates as well
as lower rates of angiographic restenosis and TVR, with
similar or lower rates of death and MI compared to BMS. 
In a direct comparison, 103 patients with unprotected
LMCA disease were randomly assigned to receive BMS
(n = 50) or DES (n = 53) implantation and were followed
for 6 months, at which time the DES group showed a
statistically significant reduction in binary restenosis (6%
vs. 22%) and target-lesion revascularization (TLR) (2% vs.
16%), as well as a significant reduction in the rate of major
adverse cardiac events (death, MI, or TLR; 13% vs. 30%),
all of which were entirely attributable to reduction in
repeat revascularization rate.
12
Safety concerns in DES  
Recently, concerns have been raised regarding the long-
term safety of DES, with particular regard to late stent
thrombosis and late mortality.
13-15 Increasing concern over
stent thrombosis, which may have more catastrophic con-
sequences in patients undergoing unprotected LMCA
stenting, and a lack of long-term clinical data, have ham-
pered the widespread use of PCI with DES as an alterna-
tive to CABG. 
However, recent data alleviate concerns about the safety
of PCI with DES in the treatment of unprotected LMCA
disease.
16-18 A recent multicenter registry evaluated the
occurrence of late and very late stent thrombosis in 731
patients undergoing elective LMCA stenting with DES.
16
At 30 months, four patients had definite stent thrombosis
(two acute, one subacute, and one late) and three had pro-
bable thrombosis, for a combined incidence of definite or
probable thrombosis of 0.95%. The cumulative rates of
death, MI, and TVR were 6.2%, 1.5%, and 12.9%, respec-
tively. Older age, lower ejection fraction, and EuroSCORE
were identified as predictors of thrombotic events. A report
from the DELFT registry, which included 358 patients
undergoing LMCA stenting with a minimum of 3 years
follow-up, noted that the incidence of definite, probable,
and possible stent thrombosis were 0.6%, 1.1%, and 4.4%,
respectively.
17 Among the overall registry population,
cardiac death occurred in 9.2% of patients, and MI, TLR,
and TVR were noted in 8.6%, 5.8%, and 14.2% of patients,
respectively. Compared to emergent PCI, elective PCI was
associated with excellent 3-year rates of mortality (6.2%
vs. 21.4%), reinfarction (8.3% vs. 10.0%), and TLR (2.8%
vs. 6.6%). In a recent clinical study, the ISAR-LEFT
MAIN trial, in which 607 patients were treated with DES,
the 2-year rate of definite or probable stent thrombosis was
about 0.5-1.0%. In a large real-world observation (the
MAIN-COMPARE registry), the incidence of definite
thrombosis at 3 years was 0.6%.
18 These results indicated
that DES implantation in patients with unprotected LMCA
disease results in relatively lower, or, at worst, similar rates
of stent thrombosis and long-term mortality than seen
when DES is used in subsets of patients with other
coronary lesion.
19 
To prevent stent thrombosis, dual antiplatelet therapy is
emphasized, and clopidogrel (75 mg daily) is recommended
for at least 1 year in patients treated with DES who are not
at an increased risk of bleeding.
20 The long-term benefits of
clopidogrel use beyond 6 or 12 months are, however, un-
clear in such patients.
21-23 Although the risk-benefit ratio of
long-term clopidogrel therapy is not well-studied, many
clinicians prolong dual antiplatelet therapy for up to several
years or indefinitely after LMCA stenting with DES.
Despite the various durations of applied clopidogrel treat-
ment (at least 3 months, to life),
16-18 the overall incidence of
early and late stent thrombosis were very low, and similar
among studies. Additional studies with large populations
and longer-term follow-ups are warranted to evaluate the
antithrombotic benefit vs. major bleeding risk of long-term
clopidogrel use, and to determine the optimal duration of
clopidogrel therapy after DES placement in patients with
LMCA disease. 
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LMCA disease depends on several clinical and anatomical
features, making optimal patient selection crucial for
appropriate treatment of LMCA disease and achievement
of favorable long-term outcomes.
18,24 In patients with very
complex anatomical features, which are not feasible for
stenting and concomitant diffuse multivessel disease,
CABG is preferred so as to avoid procedural and future
thrombotic risks and to provide more complete revascul-
arization. However, in patients with relatively simple
LMCA disease, such as ostial/shaft LMCA disease or
isolated LMCA disease (with or without one or two-vessel
involvement), PCI is an alternative, and in some cases a
preferred strategy in order to reduce surgical risks (e.g.,
stroke and in-hospital events following major surgery). 
LMCA lesion characteristics (severe calcification, distal
LMCA involvement with relation to major branches), the
extent of extra-LMCA (concomitant multivessel disease,
the status of distal run-off), and patient clinical characteris-
tics (age, diabetes, ejection fraction, and other co-morbidi-
ties) are important in patient selection. Patient/physician
preference is also influential. The selection of patients for
PCI may be optimized as follows: 1) PCI with stenting is a
reasonable option for patients with unprotected LMCA
disease at high surgical risk or with protected LMCA di-
sease, 2) patients presenting with acute coronary syndrome
who have culprit LMCA occlusion and hemodynamic
instability requiring emergent revascularization, and 3)
isolated ostial or mid-shaft LMCA disease. For patients
with anatomic and clinical characteristics suitable for both
CABG and PCI, the benefits and risks of PCI versus CABG
and patient/physician preference, need to be weighted. 
The potential benefit of bypass surgery over stenting in
patients with multi-vessel or LMCA disease is that, in
bypass surgery, a graft is placed on the midcoronary vessel
well beyond the area of disease, whereas stents directly
relieve the offending lesion. Thus, not only has the culprit
lesion been directly treated, but there are prophylactic
benefits in the event that the patient develops new disease.
If a patient receives a stent and develops a new disease
beyond the stented area, that patient is still at a very high
risk, but in patients who receive bypass grafting, the
development of a more proximal disease is irrelevant.
However, although the benefits of bypass surgery are well-
known, the CABG procedure results in a large portion of
the myocardium being supplied solely by the venous graft,
which has limited patency, whereas successful LMCA
stenting provides long-term patency and revascularization
of the entire coronary arterial vasculature.
Current evidence supporting PCI or CABG for LMCA
disease 
To date, a large body of data supports the feasibility,
efficacy, and safety of stenting as compared with CABG
for treatment of unprotected LMCA disease. We also
expect that longer-term (5-year and 10-year) data will soon
be forthcoming. 
Registry data 
Although several studies have reported on the mid-term
safety and feasibility of stenting in LMCA disease, long-
term benefits of PCI compared with bypass surgery are
less clear, in part because they have been evaluated less
extensively. Several, small observational studies have
compared PCI with stenting of unprotected LMCA to
CABG.
25-28 The early clinical events of left main stenting
are similar or superior to those of bypass surgery because
of a significant increase in periprocedural MI
25 or cerebro-
vascular events
26 in the CABG patients. Longer-term
mortality up to approximately 1 year was similar in the
PCI and the CABG groups. However, the risk of TVR was
consistently higher with PCI than with CABG.
The MAIN-COMPARE registry is the first long-term
study comparing PCI with stenting with bypass surgery for
LMCA disease.
18 This study evaluated 2,240 patients with
unprotected LMCA disease who underwent stenting
(BMS, 318 and DES, 784) or CABG (1,138) at 12 major
cardiac centers in Korea, where left-main stenting is far
more common than in Western countries. Outcome meas-
ures were compared during the first 3 years after treatment
and included death; a composite outcome of death, Q-
wave MI, or stroke; and TVR using propensity-score
matching. The risks of death and the composite of death,
Q-wave MI, or stroke were similar in the PCI and CABG
groups and these results were consistent when either BMS
or DES was compared with concurrent CABG. However,
the rate of TVR was significantly lower in the CABG
group than in the PCI group with hazard ratios varying by
the type of stent. DES recipients were almost 6-fold more
likely, and BMS recipients almost 10-fold more likely, to
require revascularization, compared to those who under-
went surgery. 
Randomized clinical trials 
The LeMANS trial was the first randomized comparison
of PCI with stenting (52 patients) and CABG (53 patients)
for the treatment of unprotected LMCA stenosis, with or
without multivessel CAD.
29 DES were placed in 35% of
PCI patients and left internal mammary artery grafts were
used in 72% of CABG patients. At 1 year, the primary
endpoint of absolute change in left ventricular ejection
fraction was significantly greater in the PCI than in the
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CABG group (3.3 ± 6.7% vs. 0.5 ± 0.8%; p = 0.047),
whereas the secondary endpoints, survival and MACCE,
were comparable in the two groups. Although this was a
prospective, randomized initial trial comparing outcomes
of stenting versus CABG for LMCA disease, the results
were limited by the small number of patients and the non-
specific and inconclusive primary endpoint chosen to
evaluate treatment effects. 
As shown in the left main subsets (348 patients treated
with CABG and 357 treated with PES) from the SYNTAX
(SYNergy Between PCI With TAXUS and Cardiac Sur-
gery) trial,
30 PCI demonstrated 1-year clinical outcomes
equivalent to those seen after standard bypass surgery. In
particular, PCI-treated patients showed a trend towards
lower MACCE rates in cases with anatomically simple
LMCA disease (LMCA only and LMCA plus single-
vessel disease), compared with CABG-treated patients.
The rate of revascularization was significantly higher in
PCI-treated patients, whereas the stroke risk was signifi-
cantly greater in CABG-treated patients. However, due to
the exploratory, hypothesis-generating nature of subgroup
analysis, results from more specific LMCA-targeted trials
are needed. The ongoing PRECOMBAT (PREmiere of
COMparison of Bypass Surgery and Angioplasty Using
Sirolimus-Eluting Stents in Patients With Unprotected Left
Main Coronary Artery Disease) trial, which is a prospec-
tive, multicenter, randomized study to compare the safety
and efficacy of SES and CABG for treatment of unpro-
tected LMCA disease with a primary study end-point of 1-
year MACCE (death, MI, stroke, and TVR), is expected to
provide a more definitive evaluation of the two primary
interventions. 
Meta-analysis and systemic review  
A recent meta-analysis, which considered results of 16
observational studies on 1,278 patients undergoing PCI
with DES for unprotected LMCA disease, showed a low
in-hospital mortality rate of 2.3% and a low mid-term mor-
tality rate of 5.5% at a median of 10 months follow-up, as
well as adjusted odds ratios for MACCE (death, MI, TVR,
or stroke) of 0.46 (0.24-0.90), favoring PCI with DES over
CABG.
31 In contrast, another systemic review suggested
that early (in-hospital, to 30 days) and longer-term (1-2
year) mortality rates were better after CABG (early, 2-4%,
average 3%; late, 5-6%, average 5%) than PCI with BMS
(early, 0-14%, average 6%; late, 3-31%, average 17%) or
DES (early, 0-10%, average 2%; late, 0-14%, average
7%).
32 However, these results should be interpreted with
caution and regarded as only exploratory findings, given
the limited number of patients, selection or publication
bias in the literature reviewed, and caveats on internal
validity of the included clinical studies. 
Based on clinical trials comparing CABG and medical
therapy, current guidelines recommend CABG as the
treatment of choice for patients with asymptomatic ische-
mia, stable angina, or unstable angina/non-ST elevation
myocardial infarction who have LMCA disease.
1 PCI can
be selectively performed in patients who are candidates for
revascularization but who are not suitable for CABG.
However, evidences indicates that stenting yields mortality
and morbidity rates that compare favorably with CABG,
suggesting that a current guideline (class III recommen-
dation of PCI for unprotected LMCA disease) may no
longer be justified. A large clinical trial (the SYNTAX
trial) showed that DES, compared with CABG, demon-
strated acceptable outcomes in patients with LMCA disease.
Also, data from large registries (the MAIN-COMPARE
and the DELFT study) from routine clinical practice and
from a DES clinical study (the ISAR-LEFT MAIN trial)
may have prompted many interventional cardiologists to
choose PCI with stenting as a good treatment option for
patients with LMCA disease. These results may inform
future guidelines and support the need for well-designed,
adequately powered, prospective, randomized trials com-
paring the two revascularization strategies in patients with
unprotected LMCA disease. In addition, the cumulative
evidence from ongoing and future clinical trials will change
the current clinical practice of revascularization for unpro-
tected LMCA disease, which was introduced several deca-
des ago and has continued without major revision to date. 
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